Astbury C, Bird H A, McLaren A M, Robins S P
Clinical Pharmacology Unit, Royal Bath Hospital, Harrogate, North Yorkshire.
Br J Rheumatol. 1994 Jan;33(1):11-5. doi: 10.1093/rheumatology/33.1.11.
The urinary excretion of the collagen crosslinking compounds pyridinoline and deoxypyridinoline have been determined in patients with morphologically different subgroups of OA and RA. There was no significant difference in pyridinoline or deoxypyridinoline excretion when patients with four grades of severity of OA were compared, although the median excretion of pyridinoline and deoxypyridinoline for the OA group as a whole was raised above values found in a healthy control population. Patients with severe or late (burnt-out) RA were found to have a significantly greater excretion of pyridinoline and deoxypyridinoline than patients with early (< 6 months duration) or mild RA.
在患有形态学上不同亚组的骨关节炎(OA)和类风湿关节炎(RA)的患者中,已对胶原交联化合物吡啶啉和脱氧吡啶啉的尿排泄情况进行了测定。当对患有四个严重程度等级的OA患者进行比较时,吡啶啉或脱氧吡啶啉的排泄量没有显著差异,尽管OA组总体的吡啶啉和脱氧吡啶啉排泄中位数高于健康对照人群中的值。发现患有重度或晚期(耗竭型)RA的患者,其吡啶啉和脱氧吡啶啉的排泄量明显高于患有早期(病程<6个月)或轻度RA的患者。